Development+of+targeted+therapies+in+treatment+of+glioblastoma.pdf

Cancer Biol Med 2015;12:223-237. doi: 10.7497/j.issn.2095-3941.2015.0020 REVIEW Development of targeted therapies in treatment of glioblastoma Yuan-Yuan Xu, Pei Gao, Ying Sun, You-Rong Duan State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200032, China ABSTRACT Glioblastoma (GBM) is a type of tumor that is highly lethal despite maximal therapy. Standard therapeutic approaches provide modest improvement in progression-free and overall survival, necessitating the investigation of novel therapies. Oncologic therapy has recently experienced a rapid evolution toward “targeted therapy”, with drugs directed against specific targets which play essential roles in the proliferation, survival, and invasiveness of GBM cells, including numerous molecules involved in signal transduction pathways. Inhibitors of these molecules have already entered or are undergoing clinical trials. However, significant challenges in their development remain because several preclinical and clinical studies present conflicting results. In this article, we will provide an up-to-date review of the current targeted therapies in GBM. KEYWORDS Glioblastoma (GBM); targeted therapy; blood-brain barrier (BBB); clinical trial Introduction 100,000 are diagnosed annually worldwide1,3-7. GBM is also one of the most lethal brain tumors, with only one-third of patients Classification and epidemiology of glioblastoma surviving for 1 year and less than 5% living beyond 5 years8,9. (GBM)